First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
Clinical trial NCT05280626 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05280626
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-25
- Primary completion
- 2025-12-31
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.